Written question asked by Chris Green (Conservative) on Wednesday, 6 March 2019, in the House of Commons. It was due for an answer on Monday, 11 March 2019. It was answered by Steve Brine (Conservative) on Friday, 15 March 2019 on behalf of the Department of Health and Social Care.
Biosimilar Medicines
- Question
-
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of NHS Improvement's metrics to support biosimilar uptake within the Model Hospital dashboard on adherence to best practice guidance on shared-decision making and patient consent, and if he will make a statement.
- Answer
-
The Department has made no assessment. NHS Improvement holds a joint role in supporting the National Health Service to use the best value biologic medicine which is part of a long standing programme of work connected to the NHS Biosimilar Medicines Steering Group, the NHS England Medicines Value Programme and the NHS Improvement Top 10 Medicines remit.
The Biosimilars Medicines Steering Group is intended to ensure appropriate use of biosimilar medicines across the NHS in England. This includes a focus on the importance of shared decision making and patient consent. The steering group has produced commissioning guidance which sets out best practice in shared decision making and which is fully endorsed by patient groups.
Secondary information
- Type
- Written question
- Reference
- 229241
- Session
- 2017-19
- Subjects
- Consent to medical treatment Biosimilar medicines
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2019-03-15 13:11:58 +0000
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/229241
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/229241
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2017-19/229241